[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics Inc (TRDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 250,784
  • Shares Outstanding, K 38,821
  • Annual Sales, $ 25,420 K
  • Annual Income, $ -143,750 K
  • EBIT $ -178 M
  • EBITDA $ -178 M
  • 60-Month Beta -0.26
  • Price/Sales 9.64
  • Price/Cash Flow N/A
  • Price/Book 0.90

Options Overview Details

View History
  • Implied Volatility 326.85% (-16.08%)
  • Historical Volatility 254.19%
  • IV Percentile 58%
  • IV Rank 24.95%
  • IV High 1,251.56% on 09/10/25
  • IV Low 19.44% on 09/09/25
  • Expected Move (DTE 5) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 4
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 753
  • Open Int (30-Day) 842
  • Expected Range 6.46 to 6.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.16
  • Number of Estimates 4
  • High Estimate $-0.99
  • Low Estimate $-1.34
  • Prior Year $-1.04
  • Growth Rate Est. (year over year) -11.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.63 +14.74%
on 05/19/26
7.41 -12.82%
on 05/14/26
-0.66 (-9.27%)
since 05/12/26
3-Month
5.63 +14.74%
on 05/19/26
16.45 -60.73%
on 05/06/26
-6.52 (-50.23%)
since 03/12/26
52-Week
4.93 +31.03%
on 08/11/25
16.45 -60.73%
on 05/06/26
-1.39 (-17.71%)
since 06/12/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are...

TRDA : 6.46 (+2.38%)
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201  -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June...

TRDA : 6.46 (+2.38%)
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired...

TRDA : 6.46 (+2.38%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are...

TRDA : 6.46 (+2.38%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are...

TRDA : 6.46 (+2.38%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA).  Such investors are...

TRDA : 6.46 (+2.38%)
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory...

TRDA : 6.46 (+2.38%)
Entrada Therapeutics Reports First Quarter 2026 Financial Results

-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201...

TRDA : 6.46 (+2.38%)
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were...

TRDA : 6.46 (+2.38%)
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion...

TRDA : 6.46 (+2.38%)

Business Summary

Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 6.90
2nd Resistance Point 6.71
1st Resistance Point 6.58
Last Price 6.46
1st Support Level 6.26
2nd Support Level 6.07
3rd Support Level 5.94

See More

52-Week High 16.45
Fibonacci 61.8% 12.05
Fibonacci 50% 10.69
Fibonacci 38.2% 9.33
Last Price 6.46
52-Week Low 4.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.